CaseVu
Current Signed Customers Expected To Generate $1M Annualized Reported Revenues From Precipio’s HemeScreen POL Offering By Q4-2021
Precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the [...]
Apr
Precipio Enters Into An At-The -Market (ATM) Financing Arrangement
NEW HAVEN, CT, (April 5th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces a new [...]
Apr
Precipio Announces 95% Annual Growth YoY And 180% Quarterly Growth YoY
HemeScreen projected to rapidly become a material revenue contributor in 2021 NEW HAVEN, CT, (March [...]
Mar
Precipio Announces Q4-2020 And Year-End Shareholder Update Call
Conference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST NEW [...]
Mar
Mr. Ron Andrews Joins Precipio’s Board Of Directors
Company Strengthens Depth of Expertise in Products Industry NEW HAVEN, CT, (March 3rd, 2021) – Specialty [...]
Mar
Mr. Richard Sandberg Is Appointed Chairman Of Precipio’s Board Of Directors
NEW HAVEN, CT, (March 3rd, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of [...]
Mar
Precipio Launches COVID-19 Antibody Testing At Point-Of-Care
Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC [...]
Jan
Precipio Signs HemeScreen™ Deals With Two Leading Oncology Groups
Partnership with ION Solutions expected to accelerate sales NEW HAVEN, CT, (January 20th, 2021) – Specialty [...]
Jan
Precipio Signs Sales & Marketing Agreement For HemeScreen™ With Major Oncology Distributor
Thousands of Oncology Practices will gain access to HemeScreen POL program NEW HAVEN, CT, (December [...]
Dec
Precipio Announces Q3-2020 Shareholder Update Call
Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST NEW [...]
Nov